Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV) Downgraded by Raymond James Financial, Inc.

Raymond James Financial, Inc. lowered shares of Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV) from an outperform rating to a market perform rating in a research note issued to investors on Monday, July 31st, MarketBeat.com reports.

Several other equities analysts also recently issued reports on NVIV. UBS AG downgraded shares of Invivo Therapeutics Holdings Corp from a strong-buy rating to an outperform rating in a research note on Friday, May 5th. ValuEngine downgraded shares of Invivo Therapeutics Holdings Corp from a sell rating to a strong sell rating in a research note on Friday, June 2nd.

Shares of Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV) opened at 1.25 on Monday. Invivo Therapeutics Holdings Corp has a 12 month low of $1.10 and a 12 month high of $7.94. The company’s market cap is $40.23 million. The firm’s 50 day moving average is $1.99 and its 200 day moving average is $3.09.

ILLEGAL ACTIVITY WARNING: “Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV) Downgraded by Raymond James Financial, Inc.” was originally reported by BNB Daily and is the property of of BNB Daily. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.baseball-news-blog.com/2017/08/19/raymond-james-financial-inc-lowers-invivo-therapeutics-holdings-corp-otcmktsnviv-to-market-perform-updated-updated.html.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Legal & General Group Plc boosted its position in shares of Invivo Therapeutics Holdings Corp by 4,427.9% in the second quarter. Legal & General Group Plc now owns 503,407 shares of the biotechnology company’s stock worth $1,359,000 after buying an additional 492,289 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Invivo Therapeutics Holdings Corp by 144.5% in the second quarter. Goldman Sachs Group Inc. now owns 167,318 shares of the biotechnology company’s stock worth $452,000 after buying an additional 98,879 shares in the last quarter. Susquehanna International Group LLP acquired a new position in shares of Invivo Therapeutics Holdings Corp during the second quarter worth about $434,000. Blair William & Co. IL acquired a new position in shares of Invivo Therapeutics Holdings Corp during the second quarter worth about $159,000. Finally, LMR Partners LLP acquired a new position in shares of Invivo Therapeutics Holdings Corp during the second quarter worth about $159,000.

About Invivo Therapeutics Holdings Corp

InVivo Therapeutics Holdings Corp., formerly Design Source, Inc, is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company’s approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury.

Receive News & Ratings for Invivo Therapeutics Holdings Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivo Therapeutics Holdings Corp and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply